1naresh
Array ( [urn:ac.highwire.org:guest:identity] => Array ( [runtime-id] => urn:ac.highwire.org:guest:identity [type] => guest [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [urn:ac.highwire.org:guest:privilege] => Array ( [runtime-id] => urn:ac.highwire.org:guest:privilege [type] => privilege-set [privilege-set] => GUEST ) ) [credentials] => Array ( [method] => guest ) ) ) 1nareshArray ( [urn:ac.highwire.org:guest:identity] => Array ( [runtime-id] => urn:ac.highwire.org:guest:identity [type] => guest [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [urn:ac.highwire.org:guest:privilege] => Array ( [runtime-id] => urn:ac.highwire.org:guest:privilege [type] => privilege-set [privilege-set] => GUEST ) ) [credentials] => Array ( [method] => guest ) ) )Table 1:Patient Demographics
Age Sex Previous Chemotherapy Previous Radiotherapy Glioma 49.9 ± 11.21 21 F/22 M 98% (20 F/22 M) 63% (6 F/10 M) Metastases 56.5 ± 11.60 18 F/22 M 68% (6 F/7 M) 85% (2 F/4 M) Overall 53.1 ± 11.80 39 F/44 M 83% (7 F/7 M) 73% (8 F/14 M)
Note:—F indicates female; M, male.